Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
All content for The Lancet Haematology in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom
The Lancet Haematology in conversation with
17 minutes
11 months ago
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom
Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/...
The Lancet Haematology in conversation with
Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
